Estimated dates.Exemption number (b)(4) permits numbering sequence to begin with 10000, to avoid duplication of report numbers due to process transition.There may be gaps in numbering for reports submitted during the transition period.The scaffold remains in the patient.Investigation is not yet complete.A follow-up report will be submitted with all additional relevant information.The absorb device is currently not commercially available in the u.S; however, it is similar to a device sold in the u.S.Na.
|
Unique device identifier (udi#): in the absence of a reported part number, the udi cannot be calculated.Exemption number e2019001.Product performance engineering reviewed the incident information; however, there was no reported device malfunction and the product was not returned as the scaffold remains in the anatomy.The reported patient effect of restenosis, as listed in the bioresorbable vascular scaffold (bvs) system, absorb, electronic instructions for use is a known adverse event associated with the use of a coronary scaffold in native coronary arteries.A review of the lot history record and complaint history of the reported lot could not be conducted because the part and lot number were not provided.Based on the case information, a conclusive cause for the reported patient effect, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to design, manufacture or labeling of the device.Report source.Initial reporter information.
|
Additional information received stating: the event did not occur in (b)(6), it occurred during the physician's fellowship program in (b)(6), u.S.A during 2015-16, around 8-12 absorb bvs were used and few incidences of in-stent restenosis were observed.
|